199 related articles for article (PubMed ID: 24572252)
1. Mechanism of the susceptibility of remodeled pulmonary vessels to drug-induced cell killing.
Ibrahim YF; Wong CM; Pavlickova L; Liu L; Trasar L; Bansal G; Suzuki YJ
J Am Heart Assoc; 2014 Feb; 3(1):e000520. PubMed ID: 24572252
[TBL] [Abstract][Full Text] [Related]
2. Reoxygenation Reverses Hypoxic Pulmonary Arterial Remodeling by Inducing Smooth Muscle Cell Apoptosis via Reactive Oxygen Species-Mediated Mitochondrial Dysfunction.
Chen J; Wang YX; Dong MQ; Zhang B; Luo Y; Niu W; Li ZC
J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28645933
[TBL] [Abstract][Full Text] [Related]
3. Bioactive fraction of Rhodiola algida against chronic hypoxia-induced pulmonary arterial hypertension and its anti-proliferation mechanism in rats.
Nan X; Su S; Ma K; Ma X; Wang X; Zhaxi D; Ge R; Li Z; Lu D
J Ethnopharmacol; 2018 Apr; 216():175-183. PubMed ID: 29325918
[TBL] [Abstract][Full Text] [Related]
4. A novel vascular homing peptide strategy to selectively enhance pulmonary drug efficacy in pulmonary arterial hypertension.
Toba M; Alzoubi A; O'Neill K; Abe K; Urakami T; Komatsu M; Alvarez D; Järvinen TA; Mann D; Ruoslahti E; McMurtry IF; Oka M
Am J Pathol; 2014 Feb; 184(2):369-75. PubMed ID: 24401613
[TBL] [Abstract][Full Text] [Related]
5. Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat.
Cotroneo E; Ashek A; Wang L; Wharton J; Dubois O; Bozorgi S; Busbridge M; Alavian KN; Wilkins MR; Zhao L
Circ Res; 2015 May; 116(10):1680-90. PubMed ID: 25767292
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMα) in chronic hypoxia- and antigen-mediated pulmonary vascular remodeling.
Angelini DJ; Su Q; Yamaji-Kegan K; Fan C; Skinner JT; Poloczek A; El-Haddad H; Cheadle C; Johns RA
Respir Res; 2013 Jan; 14(1):1. PubMed ID: 23289668
[TBL] [Abstract][Full Text] [Related]
7. Endothelial cell-related autophagic pathways in Sugen/hypoxia-exposed pulmonary arterial hypertensive rats.
Kato F; Sakao S; Takeuchi T; Suzuki T; Nishimura R; Yasuda T; Tanabe N; Tatsumi K
Am J Physiol Lung Cell Mol Physiol; 2017 Nov; 313(5):L899-L915. PubMed ID: 28798259
[TBL] [Abstract][Full Text] [Related]
8. PAR-2 inhibition reverses experimental pulmonary hypertension.
Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension.
Lan B; Hayama E; Kawaguchi N; Furutani Y; Nakanishi T
PLoS One; 2015; 10(1):e0117211. PubMed ID: 25629315
[TBL] [Abstract][Full Text] [Related]
10. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
Kikuchi N; Satoh K; Kurosawa R; Yaoita N; Elias-Al-Mamun M; Siddique MAH; Omura J; Satoh T; Nogi M; Sunamura S; Miyata S; Saito Y; Hoshikawa Y; Okada Y; Shimokawa H
Circulation; 2018 Aug; 138(6):600-623. PubMed ID: 29636330
[TBL] [Abstract][Full Text] [Related]
11. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension.
Paulin R; Meloche J; Jacob MH; Bisserier M; Courboulin A; Bonnet S
Am J Physiol Heart Circ Physiol; 2011 Nov; 301(5):H1798-809. PubMed ID: 21890685
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib reverses pulmonary arterial hypertension.
Wang X; Ibrahim YF; Das D; Zungu-Edmondson M; Shults NV; Suzuki YJ
Cardiovasc Res; 2016 May; 110(2):188-99. PubMed ID: 26952044
[TBL] [Abstract][Full Text] [Related]
13. Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.
Christou H; Hudalla H; Michael Z; Filatava EJ; Li J; Zhu M; Possomato-Vieira JS; Dias-Junior C; Kourembanas S; Khalil RA
J Pharmacol Exp Ther; 2018 Feb; 364(2):258-274. PubMed ID: 29212831
[TBL] [Abstract][Full Text] [Related]
14. Reversal effects of low-dose imatinib compared with sunitinib on monocrotaline-induced pulmonary and right ventricular remodeling in rats.
Leong ZP; Okida A; Higuchi M; Yamano Y; Hikasa Y
Vascul Pharmacol; 2018 Jan; 100():41-50. PubMed ID: 29100963
[TBL] [Abstract][Full Text] [Related]
15. Intermedin modulates hypoxic pulmonary vascular remodeling by inhibiting pulmonary artery smooth muscle cell proliferation.
Mao SZ; Fan XF; Xue F; Chen R; Chen XY; Yuan GS; Hu LG; Liu SF; Gong YS
Pulm Pharmacol Ther; 2014 Feb; 27(1):1-9. PubMed ID: 23796770
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel Reverses Pulmonary Vascular Remodeling by Decreasing Autophagy and Resolves Right Ventricular Fibrosis.
Ibrahim YF; Shults NV; Rybka V; Suzuki YJ
J Pharmacol Exp Ther; 2017 Oct; 363(1):20-34. PubMed ID: 28760737
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
18. P21-dependent protective effects of a carbon monoxide-releasing molecule-3 in pulmonary hypertension.
Abid S; Houssaïni A; Mouraret N; Marcos E; Amsellem V; Wan F; Dubois-Randé JL; Derumeaux G; Boczkowski J; Motterlini R; Adnot S
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):304-12. PubMed ID: 24334871
[TBL] [Abstract][Full Text] [Related]
19. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.
Preston IR; Sagliani KD; Warburton RR; Hill NS; Fanburg BL; Jaffe IZ
Am J Physiol Lung Cell Mol Physiol; 2013 May; 304(10):L678-88. PubMed ID: 23457185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
